Compile Data Set for Download or QSAR
Report error Found 692 for UniProtKB: P33534
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235813(US9359399, 27)
Affinity DataEC50:  0.00560nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235795(US9359399, 7)
Affinity DataEC50:  0.0120nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274048(N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-d...)
Affinity DataIC50: 0.0190nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235812(US9359399, 26)
Affinity DataEC50:  0.0194nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235803(US9359399, 16)
Affinity DataEC50:  0.0210nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235815(US9359399, 31)
Affinity DataEC50:  0.0216nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235792(US9359399, 36)
Affinity DataEC50:  0.0234nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235802(US9359399, 15)
Affinity DataEC50:  0.0280nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50346951(CHEMBL1795714 | CHEMBL1795711)
Affinity DataKi:  0.0300nMAssay Description:Displacement of [125I]-BNtxA from mouse cloned KOR-1 expressed in CHO cell membrane after 90 minsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2013
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235811(US9359399, 25)
Affinity DataEC50:  0.0314nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235786(US9359399, 13)
Affinity DataEC50:  0.0320nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235784(US9359399, 5)
Affinity DataEC50:  0.0340nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274519((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.0350nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235818(US9359399, 35)
Affinity DataEC50:  0.0359nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235810(US9359399, 24)
Affinity DataEC50:  0.0360nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235794(US9359399, 6)
Affinity DataEC50:  0.0360nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235804(US9359399, 17)
Affinity DataEC50:  0.0390nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235796(US9359399, 8)
Affinity DataEC50:  0.0430nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235787(US9359399, 1)
Affinity DataEC50:  0.0430nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235814(US9359399, 29)
Affinity DataEC50:  0.0464nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235785(US9359399, 2 | CVD-0019439)
Affinity DataEC50:  0.0480nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235816(US9359399, 32)
Affinity DataEC50:  0.0485nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274401((2E)-N-[(5R,6S)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.0490nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235799(US9359399, 11)
Affinity DataEC50:  0.0520nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235793(US9359399, 3)
Affinity DataEC50:  0.0520nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235800(US9359399, 12)
Affinity DataEC50:  0.0550nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235789(US9359399, 28)
Affinity DataEC50:  0.0582nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274178((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.0700nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235783(US9359399, 4)
Affinity DataEC50:  0.0750nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235791(US9359399, 33)
Affinity DataEC50:  0.0767nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235797(US9359399, 9)
Affinity DataEC50:  0.0780nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50346952(CHEMBL1795715 | CHEMBL1795712)
Affinity DataKi:  0.0800nMAssay Description:Displacement of [125I]-BNtxA from mouse cloned KOR-1 expressed in CHO cell membrane after 90 minsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2013
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235788(US9359399, 23)
Affinity DataEC50:  0.0910nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235809(US9359399, 22)
Affinity DataEC50:  0.0950nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274256((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.100nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274255((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.100nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50118178(CHEMBL3613172)
Affinity DataKi:  0.113nMAssay Description:Displacement of [3H]U69,593 from KOR in mouse whole brain membranes without cerebellumMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50035476(N-[(S)-1-(3-Amino-phenyl)-2-pyrrolidin-1-yl-ethyl]...)
Affinity DataIC50: 0.120nMAssay Description:Inhibitory activity against Opioid receptor kappa 1 in electrically stimulated mouse vas deferens (MVD) preparation.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/3/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50637030(CHEMBL5523574)
Affinity DataKd:  0.120nMAssay Description:Displacement of [3H]diprenorphine from mouse KOR expressed in CHO cells assessed as dissociation constant incubated for 1.5 hrs by radioligand bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235790(US9359399, 30)
Affinity DataEC50:  0.129nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50637024(CHEMBL5542938)
Affinity DataKd:  0.130nMAssay Description:Displacement of [3H]diprenorphine from mouse KOR expressed in CHO cells assessed as dissociation constant incubated for 1.5 hrs by radioligand bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50118191(CHEMBL3613173)
Affinity DataKi:  0.136nMAssay Description:Displacement of [3H]U69,593 from KOR in mouse whole brain membranes without cerebellumMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50637036(CHEMBL5560353)
Affinity DataKd:  0.140nMAssay Description:Displacement of [3H]diprenorphine from mouse KOR expressed in CHO cells assessed as dissociation constant incubated for 1.5 hrs by radioligand bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274175((2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataIC50: 0.166nMAssay Description:Agonist activity at kappa opioid receptor in ddy mouse vas deferens assessed as inhibition of electric stimulation-induced contractionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50637038(CHEMBL5555907)
Affinity DataKd:  0.170nMAssay Description:Displacement of [3H]diprenorphine from mouse KOR expressed in CHO cells assessed as dissociation constant incubated for 1.5 hrs by radioligand bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50274347((2E)-N-[(5R,6R)-17-(cyclopropylmethyl)-4,5-epoxy-3...)
Affinity DataKi:  0.178nMAssay Description:Displacement of [3H]U69,593 from KOR in mouse whole brain membranes without cerebellumMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2016
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50506217(CHEMBL4458688)
Affinity DataKi:  0.200nMAssay Description:Displacement of [3H]-Naltrindole from mouse kappa opioid receptor expressed in CHO cells incubated for 1.5 hrs by competitive radioligand binding ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50506211(CHEMBL4444746)
Affinity DataKi:  0.200nMAssay Description:Displacement of [3H]-Naltrindole from mouse kappa opioid receptor expressed in CHO cells incubated for 1.5 hrs by competitive radioligand binding ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50574769(CHEMBL4870603)
Affinity DataKi:  0.200nMAssay Description:Positive allosteric modulator activity in mouse kappa opioid receptor stably expressed in HEK293 cell membrane assessed as binding affinity of dyn A1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/23/2022
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50118177(CHEMBL3613171)
Affinity DataKi:  0.204nMAssay Description:Displacement of [3H]U69,593 from KOR in mouse whole brain membranes without cerebellumMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2016
Entry Details Article
PubMed
Displayed 1 to 50 (of 692 total ) | Next | Last >>
Jump to: